Prioritise protein Protein is a key nutrient to focus on when losing weight taking GLP-1s, since faster weight loss can result in muscle mass loss
The Settlement Money The money set aside to address opioid addiction comes from companies tied to the crisis
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)

Clinically, large randomized trials report kidney-related benefits with GLP-1 receptor agonists, most consistently reductions in albuminuria, with additional signals for slower estimated glomerular filtration rate (eGFR) decline in higher-risk subgroups [4, 5]
To qualify for a GLP-1 prescribed for weight loss, you need a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity, and no contraindications in your medical history
It's not uncommon to see BPC 157 mentioned in forums and weight-gain testimonials